Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable

Science Daily - 3 Jun 2016 19:03
Further advantages of the drug Cobimetinib in comparison with the comparator therapy resulted from the analyses subsequently submitted by the drug manufacturer in the commenting procedure.
Full Article at Science Daily

More Science News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard